OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
November 03, 2022
High-concentration injectable formulations present unique challenges.
Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.
The state of oral solid dose manufacturing is influenced by new approaches, novel technologies, and the structural evolution of the raw materials market.
Adherence to detail and thorough project management are required for successful tech transfer and scale up.
November 02, 2022
Pharma companies set goals and adopt more sustainable alternatives.
New medications show exciting outcomes for weight loss.
Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.
November 01, 2022
FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.
Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany.
October 31, 2022
Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.